Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6605 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2024-11-15 (pharmnewskz.com)
Innovative Solutions in Medicine: Game-Changing Research
Kazakhstan Pharmaceutical Bulletin is an information and analytical newspaper for pharmacists. All about the pharmaceutical market. Pharmacy news, pharmaceuticals, pharmacy, healthcare, legislation. Electronic version of KFV
Read more
2024-09-13 (pharmnewskz.com)
Biogen Tried New Spinraza Treatment for SMA with Higher Doses
Kazakhstan Pharmaceutical Bulletin is an information and analytical newspaper for pharmacists. All about the pharmaceutical market. Pharmacy news, pharmaceuticals, pharmacy, healthcare, legislation. Electronic version of KFV
Read more
2021-09-29 (rte.ie)
Perrigo settles €1.64bn tax bill with Revenue for €297m
Drugmaker company, Perrigo, has settled its long-running dispute with Revenue over a €1.64bn tax bill, for just under €300m.
Read more
2016-04-13 (dagensmedicin.se)
The director general ran over his own experts on MS drugs
The Director General of the National Board of Health and Welfare runs over his own experts. Doctors are outraged while drug companies are happy that a recommendation about the drug Mabthera is not included in the new guidelines for multiple sclerosis, ms.
Read more
(nationalezorggids.nl)
Bruins is negotiating a reimbursement arrangement for MS drug Fampyra
In recent weeks, Minister Bruins of Medical Care has had a number of discussions with Biogen, the manufacturer of the MS drug Fampyra. The outcome is that Biogen sets up a reimbursement scheme in which patients can - retroactively - immediately receive a significant part of the purchase costs of the medicine Fampyra back from Biogen through a declaration. Bruins informed the House of Representatives of this yesterday, the government reports.
Read more
(devdiscourse.com)
Health News Roundup: US FDA approves Biogen's ALS drug; North Dakota governor signs strict abortion bill into law and more | Health
But rape and incest victims would have to carry their pregnancies to term unless "the probable gestational age of the unborn child is six weeks or less," Senate Bill 2150 says. Biogen trims pipeline programs to cut costs, focus on Alzheimer 's drug launch Biogen Inc said on Tuesday it will pause or
Read more